 DURHAM, N.C.--BUSINESS WIRE--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies, today announced that the following poster, highlighting a preclinical research collaboration using its ARCUS genome editing platform for treatment of transthyretin amyloidosis ATTR, will be presented at the upcoming American Society of Gene Cell Therapy ASGCT Annual Meeting, scheduled for May 11-14, 2021. 